// App-Quantinova.ai

: Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Researchers

Presenter

  • Kallesh D. Jayappa

Principal Investigators

  • Luke R. Vass

  • Caroline Farrington

  • Anuradha Illendula

  • Susan Walker

  • Michael E. Williams

  • Craig A. Portell

  • Todd Fox

  • Goutham Narla

  • Mark Kester

Medical Centers

  • Division of Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, VA

  • NanoStar, Charlottesville, VA

  • Department of Pharmacology, University of Virginia School of Medicine, Charlottesville, VA

  • UVA Comprehensive Cancer Center, University of Virginia, Charlottesville, VA

  • Department of Medicine, University of Michigan, Ann Arbor, MI

  • Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Chronic Lymphocytic Leukemia

  • Non-Hodgkin's Lymphoma

  • Mantle cell lymphoma

  • Hodgkin's Lymphoma

  • Advanced refractory tumors

  • Non‐Hodgkin Lymphoma

  • Lymphomas

  • Solid malignancies

Biomarkers

  • p53

  • B-cell lymphoma-extra large

  • B-cell lymphoma 2

  • Myeloid Cell Leukemia 1

  • Nucleoside diphosphate kinase A

  • Peripheral blood mononuclear cell

  • cMYC

  • Protein Phosphatase 2 Phosphatase Activator

Drug/Treatment

  • Venetoclax

  • Ibrutinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Bioavailability

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved